$-0.25 EPS Expected for ChemoCentryx, Inc. (CCXI)

July 14, 2018 - By Christine McCrea

ChemoCentryx, Inc. (NASDAQ:CCXI) LogoInvestors sentiment decreased to 1 in Q1 2018. Its down 0.30, from 1.3 in 2017Q4. It turned negative, as 10 investors sold ChemoCentryx, Inc. shares while 36 reduced holdings. 24 funds opened positions while 22 raised stakes. 24.22 million shares or 3.03% more from 23.51 million shares in 2017Q4 were reported.
Thompson Davis And invested 0.02% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Rhumbline Advisers has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Bank Of Montreal Can has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 10,828 shares. Sei Investments invested in 0% or 2,817 shares. Moreover, Tiaa Cref Management Ltd has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 211,426 shares. Pub Employees Retirement Of Ohio stated it has 117,524 shares or 0.01% of all its holdings. Acadian Asset Ltd Limited Liability Company holds 0.03% or 521,864 shares in its portfolio. Prelude Mgmt Ltd Liability Com accumulated 983 shares or 0% of the stock. J Goldman Company Limited Partnership has 0.02% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Renaissance Techs Limited Liability Com invested 0.01% in ChemoCentryx, Inc. (NASDAQ:CCXI). Manufacturers Life Ins The has 20,352 shares. Blackrock Incorporated invested in 0% or 2.57 million shares. Group Inc One Trading Ltd Partnership has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 3,961 shares. Northern Tru holds 276,280 shares. Spark Inv Mngmt Ltd Com invested in 62,600 shares or 0.05% of the stock.

Since May 1, 2018, it had 0 insider buys, and 12 sales for $7.89 million activity. The insider Schall Thomas J. sold 50,000 shares worth $550,858. 100 shares were sold by KANAYA SUSAN M, worth $1,410 on Friday, June 29.

Analysts expect ChemoCentryx, Inc. (NASDAQ:CCXI) to report $-0.25 EPS on August, 14.They anticipate $0.06 EPS change or 31.58 % from last quarter’s $-0.19 EPS. After having $-0.19 EPS previously, ChemoCentryx, Inc.’s analysts see 31.58 % EPS growth. The stock decreased 0.22% or $0.03 during the last trading session, reaching $13.58. About 209,220 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 83.50% since July 14, 2017 and is uptrending. It has outperformed by 70.93% the S&P500.

ChemoCentryx, Inc. (NASDAQ:CCXI) Ratings Coverage

Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ChemoCentryx had 4 analyst reports since March 13, 2018 according to SRatingsIntel. The firm earned “Overweight” rating on Tuesday, March 13 by JP Morgan.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $667.46 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It has a 46.83 P/E ratio. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe Crohn's diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: